Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on May 02, 2025. The filing was submitted on May 06, 2025. The transaction was executed by Citigroup Global Markets Limited as part of GSK's existing share buyback programme under a non-discretionary agreement entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific repurchase of ordinary shares rather than operational financial results (revenue, profit, or cash flow).
- Shares Purchased: 699,344 ordinary shares.
- Price Range: Lowest price paid was 1,449.50 GBp; highest price paid was 1,478.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,465.37 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, GSK holds 206,209,407 ordinary shares in treasury.
- Shares in Issue: 4,109,037,095 ordinary shares (excluding treasury shares).
- Total Voting Rights: 4,109,037,095.
Material Changes and Programme Progress
Since the commencement of the current buyback agreement on February 24, 2025, GSK has purchased a total of 37,139,104 ordinary shares. The shares purchased in this transaction are held as Treasury shares. The filing does not provide comparative operational financial data (e.g., revenue or profit changes) as it is a disclosure of a capital transaction.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in GSK's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new specific guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (37,139,104 shares).
- Confirm the updated count of treasury shares held (206,209,407 shares).
- Review the total voting rights denominator (4,109,037,095) for disclosure threshold calculations under FCA rules.
- Check the specific VWAP of 1,465.37 GBp against market closing prices for May 02, 2025.
- Refer to the referenced Form 20-F (2024) and Q1 2025 results for detailed operational risk factors and financial performance.